The changing landscape of treatment for acquired hemophilia A

Acquired hemophilia A (AHA) is a rare acquired autoimmune disorder caused by autoantibodies against coagulation factor VIII (FVIII), which cause a hemorrhagic diathesis, not rarely of severe degree. Standard treatment consists of bleeding control with bypassing agents (recombinant activated factor...

Full description

Bibliographic Details
Published in:Bleeding, Thrombosis and Vascular Biology
Main Authors: Massimo Franchini, Daniele Focosi
Format: Article
Language:English
Published: PAGEPress Publications 2025-01-01
Subjects:
Acquired Hemophilia A
FVIII inhibitor
rituximab
emicizumab
Online Access:https://www.btvb.org/btvb/article/view/157

Internet

https://www.btvb.org/btvb/article/view/157

Similar Items